Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

December 26, 2026

Study Completion Date

December 30, 2026

Conditions
Diabetes Mellitus Type 2Glycemic Control for Diabetes Mellitus
Interventions
DRUG

Trelagliptin 100 mg

Trelagliptin will be administered as oral tablets at a dose of 100 mg once weekly for 3 months. Participants will continue background metformin therapy as prescribed. Trelagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and differs from daily DPP-4 inhibitors due to its longer duration of action, allowing weekly dosing.

DRUG

Sitagliptin 100mg OD

Sitagliptin will be administered as oral tablets at a dose of 100 mg once daily for 3 months. Participants will continue background metformin therapy as prescribed. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for type 2 diabetes mellitus and requires daily dosing.

Trial Locations (1)

25120

Khyber Teaching Hospital / Khyber Medical College, Peshawar

All Listed Sponsors
lead

Khyber Medical College, Peshawar

OTHER